WO2006121943A3 - Method for the treatment of magnesium and potassium deficiencies - Google Patents

Method for the treatment of magnesium and potassium deficiencies Download PDF

Info

Publication number
WO2006121943A3
WO2006121943A3 PCT/US2006/017562 US2006017562W WO2006121943A3 WO 2006121943 A3 WO2006121943 A3 WO 2006121943A3 US 2006017562 W US2006017562 W US 2006017562W WO 2006121943 A3 WO2006121943 A3 WO 2006121943A3
Authority
WO
WIPO (PCT)
Prior art keywords
magnesium
highly bioavailable
magnesium salt
levels
intracellular
Prior art date
Application number
PCT/US2006/017562
Other languages
French (fr)
Other versions
WO2006121943A2 (en
Inventor
Christopher Offen
Stephen Brandon
Charles Harrison
Charles White
Jeffrey Kluger
Original Assignee
Niche Pharmaceuticals Inc
Christopher Offen
Stephen Brandon
Charles Harrison
Charles White
Jeffrey Kluger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/123,284 external-priority patent/US20060252830A1/en
Priority claimed from US11/123,285 external-priority patent/US20060252831A1/en
Application filed by Niche Pharmaceuticals Inc, Christopher Offen, Stephen Brandon, Charles Harrison, Charles White, Jeffrey Kluger filed Critical Niche Pharmaceuticals Inc
Publication of WO2006121943A2 publication Critical patent/WO2006121943A2/en
Publication of WO2006121943A3 publication Critical patent/WO2006121943A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Abstract

A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt in accordance with the present invention also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy.
PCT/US2006/017562 2005-05-06 2006-05-05 Method for the treatment of magnesium and potassium deficiencies WO2006121943A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/123,284 2005-05-06
US11/123,284 US20060252830A1 (en) 2005-05-06 2005-05-06 Method for the treatment of magnesium and potassium deficiencies
US11/123,285 2005-05-06
US11/123,285 US20060252831A1 (en) 2005-05-06 2005-05-06 Method for the treatment of magnesium and potassium deficiencies

Publications (2)

Publication Number Publication Date
WO2006121943A2 WO2006121943A2 (en) 2006-11-16
WO2006121943A3 true WO2006121943A3 (en) 2009-04-30

Family

ID=37397164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/017562 WO2006121943A2 (en) 2005-05-06 2006-05-05 Method for the treatment of magnesium and potassium deficiencies

Country Status (1)

Country Link
WO (1) WO2006121943A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2467754C2 (en) * 2011-02-28 2012-11-27 Всероссийское общество изоретателей и рационализаторов Method for prevention of heart rhythm disorder in cardiac surgeries
US10890577B2 (en) 2016-05-19 2021-01-12 Tabula Rasa Healthcare, Inc. Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119794A1 (en) * 1999-01-08 2003-06-26 Bacaner Marvin B. Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119794A1 (en) * 1999-01-08 2003-06-26 Bacaner Marvin B. Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices

Also Published As

Publication number Publication date
WO2006121943A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
JP2010525050A5 (en)
WO2008060964A3 (en) Unit dosage package and methods for administering weight loss medications
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2005082414A3 (en) Concomitant drugs of a sulfonamide and another therapeutic agent
WO2006063841A3 (en) Trycyclic heterocycles, their manufacture and use as pharmaceutical agents
WO2006050250A3 (en) Dose forms comprising vx-950 and their dosage regimen
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
HRP20100210T1 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
WO2007131154A3 (en) Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2008062273A8 (en) Solid oral dosage form having antidiabetic drug combination
MX2010005385A (en) Topical drugs for use in antifungal therapy.
WO2009134079A3 (en) Pharmaceutical formulation
SI1680128T1 (en) Myo-inositol hexaphosphate for topical use
FI3229828T3 (en) Insulin glargine/lixisenatide fixed ratio formulation
CA2736751A1 (en) Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2006121943A3 (en) Method for the treatment of magnesium and potassium deficiencies
WO2003032946A3 (en) Ph-sensitive liposomes for targeted drug delivery
WO2007086978A3 (en) Azithromycin for treatment of granulomatous rosacea
WO2004062582A3 (en) Combination therapy for anticoagulation
BRPI0510820A (en) pharmaceutical composition, unit dosage form and its uses
BRPI0510855A (en) medicament in film form for oral administration and use of pharmaceutically acceptable estriol and / or estriol esters
WO2004090537A3 (en) Methods to individualize combination therapy
Ward et al. Rilpivirine/tenofovir/emtricitabine fixed‐dose combination is an efficacious and well‐tolerated “switch” regimen for patients on therapy
WO2007054139A3 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06759228

Country of ref document: EP

Kind code of ref document: A2